CA-IKOTEK
20.11.2023 15:01:29 CET | Business Wire | Press release
Ikotek, the leading IoT original design manufacturer (ODM), announces with immediate effect the appointment of Mathi Gurusamy as its new Chief Operating Officer (COO). In his new role, Mathi will be responsible for overseeing the company's day-to-day operations, driving strategic initiatives, and contributing to Ikotek's continued growth and success.
Mathi Gurusamy brings a wealth of expertise with over 20 years of experience in the IoT sector and electronic device industry to Ikotek. Prior to joining Ikotek, Mathi held CEO and COO positions at Mobilogix and Telit for the last 15 years. Most recently, Mathi served as Telit Cinterion’s president of its IoT solutions division after the company had acquired Mobilogix in June 2022. Renowned for his adeptness in transforming start-ups into thriving enterprises, Mathi boasts a proven track record. His achievements include securing Fortune 500 companies as clients and cultivating strategic alliances with pivotal partners in the wireless industry.
With a demonstrated ability to effectively manage and drive critical business requirements, Mathi will play a pivotal role in propelling Ikotek's sustained growth and success. His robust leadership skills and strategic vision will help scale Ikotek's business objectives in the US and globally, ensuring a seamless alignment of the company’s services and delivery functions, and continue to deliver significant business impact to Ikotek’s OEM customers globally.
“We are delighted to welcome Mathi Gurusamy to Ikotek as our new COO,” commented Joe Peterson, Ikotek CEO. “His proven track record in the IoT industry and his strategic mindset make him an excellent fit for our organization. Mathi joining Ikotek is a strong endorsement and I am confident that Mathi's leadership will play a key role in advancing Ikotek's mission and ensuring our continued growth."
Mathi Gurusamy expressed his enthusiasm for joining Ikotek, stating, "I am thrilled to be part of the Ikotek team and excited about the opportunity to contribute to the company's impressive growth history. Ikotek has a strong reputation for innovation and commercial excellence across the IoT ecosystem. The ambitious growth vision and strategy is only possible with the massive investment Ikotek and its parent company Quectel has undertaken. I look forward to working with the most talented team in the industry to drive operational efficiency and deliver excellent value to our customers."
As a vital component of the Quectel family and leveraging the significant eco-system synergies of the parent company, Ikotek stands out as the only global ODM exclusively dedicated to IoT. Providing an all-encompassing suite of IoT solutions, Ikotek serves as a comprehensive one-stop-shop covering design and development, hardware construction, testing and verification, product validation, software development, manufacturing, and certification. This integrated approach ensures the delivery of top-tier products and services aimed at minimizing complexity, accelerating time to market, mitigating risks, and optimizing costs. Ikotek's commitment lies in delivering high-quality solutions that resonate with the evolving demands of the IoT landscape.
About Ikotek USA, Inc.
Headquartered in San Diego, California, Ikotek’s core focus is on the enterprise market as it looks to develop ODM solutions to take full advantage of IoT, covering technologies from cellular connectivity, including NB-IoT and 5G, to satellite connections and from well-established IT to relative newcomers such as artificial intelligence IoT (AIoT).
For more information: www.ikotek.com or LinkedIn
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231120698687/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 13:02:00 CEST | Press release
New platform brings real-time electrical control to coiled tubing intervention, enabling greater precision, visibility and efficiency across intervention operations SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased p
Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 13:01:00 CEST | Press release
By transforming authoritative legal content into structured legal intelligence, Wolters Kluwer gives AI the context and relationships needed to deliver deeper research and higher-quality results Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI c
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release
Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
